Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | OTC | P00480 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604855 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL8975661 | 1.00 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL27482850 | 0.98 | MEN1 (0.44) | MEN1GAAKMT2AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL8376792 | 0.98 | MEN1 (0.44) | MEN1GAAKMT2AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL29398231 | 0.98 | MEN1 (0.44) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL5847744 | 0.89 | MEN1 (0.41) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL20468063 | 0.88 | MEN1 (0.37) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL14414714 | 0.88 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL14090836 | 0.88 | MEN1 (0.45) | MEN1GAAKMT2AMAOAMAOB | |
| SCHEMBL30860176 | 0.88 | MEN1 (0.47) | MEN1GAAKMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051554-A | Lipid removal in detergents | 诺维信公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | SPARK BIOPHARMA, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-117897386-A | Benzopyran derivatives and uses thereof | 斯帕克生物制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-116693653-B | Preparation method for large-scale production of somalupeptide | 杭州湃肽生化科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116693653-A | Preparation method for large-scale production of somalupeptide | 杭州湃肽生化科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023277656-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | (주)스파크바이오파마 | 2023-01-05 | — | — | WO | disclosed |
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| US-4572894-A | USING AMINOACYL-TRNA SYNTHETASE AS CONDENSING AGENT | Imahori, Kazutomo (JP) | 1986-02-25 | — | — | US | disclosed |
| EP-0086053-A1 | Process for synthesizing peptides or peptide derivatives | Imahori, Kazutomo (JP) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | MYD88, MYADM, CD14 | MEN1 1621/4885GAA 1713/4885KMT2A 3141/4885 |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | GPR119, GLP1R, GCGR | MEN1 4058/4885GAA 1941/4885KMT2A 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.